Anbio Biotechnology Class A (NNNN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Anbio Biotechnology Class A stock $2.70, price $3.89, that is 30.6% below the price, quality 71 out of 100. Rating: overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
21‑month range $3.13 – $52.10 · fair‑value band $2.07 – $3.33 · the $3.89 price screens above the $2.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Anbio Biotechnology Class A Ordinary Shares in your weekly email
Every Wednesday you see whether Anbio Biotechnology Class A Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.
Show moreShow less
The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Stock analysis
Anbio Biotechnology Class A (NNNN) currently trades at $3.89, while our model-based Fair Value estimate is $2.70, 31% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $4.97 per share, and 2 of the 14 models we run sit above the $3.89 price.
Bear case: the Asset-Based group reads lowest at $0.6900, and 12 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $2.07 (bear) to $3.33 (bull), the price of $3.89 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Anbio Biotechnology Class A Ordinary Shares reported revenue of $9.8M in FY2025 versus $4.4M in FY2021, a compound +21.8%/yr. Reported net income was $7.2M in FY2025, compounding +29.9%/yr from FY2021.
Key figures
Market cap $194M Micro · P/E ratio 25.9 · P/S ratio 22.4 · EPS (TTM) $0.1500 · Net margin 74.1% · Return on equity 27.1% · Return on assets (EBIT) 33.5% (5-year average) · Operating margin 59.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 89 out of 100 (low confidence).
What moves the price
The share trades about 91% below its 52-week high and 24% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −31%, NNNN screens cheaper than that median.
Fair Value models
Bear$2.07Fair Value $2.70Bull$3.33
Price $3.89 · Downside -30.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1282 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+19.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.4%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+45.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+45.9%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.56% → 67%
2025 sits 194% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Anbio Biotechnology Class A Ordinary Shares with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside−30.6% · Below median
Profitability
Return on equity (12 months)27.1% · Top 25%
Return on assets23.9% · Top 25%
Net margin (12 months)74.1% · Top 25%
Operating margin (12 months)59.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)73.9% · Top 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)25.9× · Pricier than median
P/B6.42× · Priciest 25%
P/S (12 months)22.39× · Priciest 25%
EV/EBITDA28.5× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)100· sector 40
PAST (return on equity)100· sector 31
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Anbio Biotechnology Class A Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/NNNN
Frequently asked questions
Is Anbio Biotechnology Class A (NNNN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $2.70 versus a price of $3.89, about 31% lower (overvalued).
What is the fair value of NNNN?
Our model-based fair value for Anbio Biotechnology Class A is $2.70 (as of Nov 8, 2026), built from audited fundamentals. The current price: $3.89.
What is the quality score of NNNN?
Anbio Biotechnology Class A has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anbio Biotechnology Class A (NNNN)?
Our model-based price target is the fair value of $2.70 (as of Nov 8, 2026) from 14 valuation models. Cautious scenario $2.07, optimistic scenario $3.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Anbio Biotechnology Class A Ordinary Shares stock forecast for 2026?
Our models put fair value at $2.70, about 31% lower versus a price of $3.89 (overvalued). Cautious scenario $2.07, optimistic scenario $3.33. The calculation is refreshed regularly with new filings.
What is the revenue of Anbio Biotechnology Class A (NNNN)?
Anbio Biotechnology Class A reported trailing-twelve-month revenue of about $8.6M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Anbio Biotechnology Class A (NNNN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anbio Biotechnology Class A it is $2.70 per share (as of Nov 8, 2026), against a price of $3.89. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Anbio Biotechnology Class A Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 8, 2026, NNNN trades above its calculated fair value: price $3.89, fair value $2.70, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NNNN?
No. The price is what the market pays today ($3.89); the fair value is what the company's own numbers justify ($2.70). For Anbio Biotechnology Class A the two are $1.19 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anbio Biotechnology Class A Ordinary Shares worth?
The market values Anbio Biotechnology Class A at about $194M (market capitalisation, as of Nov 8, 2026). Per share that is $3.89; our models calculate a fair value of $2.70 per share.
What do the bullish and bearish scenarios say about NNNN?
Our models span a range for Anbio Biotechnology Class A: cautious scenario $2.07, base $2.70, optimistic $3.33 per share (as of Nov 8, 2026, price $3.89). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NNNN?
Anbio Biotechnology Class A trades at a price-to-earnings ratio of 25.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.70 is built from several models across several years. Other multiples: P/B 6.4, P/S 22.4, EV/EBITDA 28.5.
How solid is the balance sheet of Anbio Biotechnology Class A (NNNN)?
Balance-sheet figures for Anbio Biotechnology Class A (as of Nov 8, 2026): return on equity 27.1%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is NNNN from its 52-week high?
Anbio Biotechnology Class A trades at $3.89, about 91% below its 52-week high of $41.11 and 24% above the low of $3.13 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.70 is for.
Which stocks are comparable to Anbio Biotechnology Class A Ordinary Shares?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anbio Biotechnology Class A Ordinary Shares stock attractive at the current price?
The data as of Nov 8, 2026: price $3.89, calculated fair value $2.70 (−31%), Quality Score 71/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NNNN calculated?
We run Anbio Biotechnology Class A through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $2.70 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Anbio Biotechnology Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anbio Biotechnology Class A (NNNN)?
The closing price on Nov 6, 2026 was $3.89. Our model-based fair value is $2.70, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anbio Biotechnology Class A Ordinary Shares right now?
The price sits above even our optimistic bull case ($3.33). The favourable scenario is already priced in. Solid but not exceptional quality (71/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Anbio Biotechnology Class A
How large is the market capitalisation of Anbio Biotechnology Class A (NNNN)?
The market capitalisation of Anbio Biotechnology Class A is $194M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anbio Biotechnology Class A (NNNN)?
The price-to-sales ratio of Anbio Biotechnology Class A is 22.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Anbio Biotechnology Class A (NNNN)?
Earnings per share at Anbio Biotechnology Class A are $0.1500 (price ÷ EPS = P/E 25.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Anbio Biotechnology Class A (NNNN)?
The net margin of Anbio Biotechnology Class A is 74.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anbio Biotechnology Class A (NNNN)?
The return on equity (ROE) of Anbio Biotechnology Class A is 27.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anbio Biotechnology Class A (NNNN)?
On an EBIT basis the return on assets of Anbio Biotechnology Class A is 33.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anbio Biotechnology Class A (NNNN)?
The operating margin of Anbio Biotechnology Class A is 59.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anbio Biotechnology Class A (NNNN)?
Revenue at Anbio Biotechnology Class A is growing +73.9% versus a year earlier (3y avg −25.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Anbio Biotechnology Class A (NNNN)?
Earnings per share at Anbio Biotechnology Class A are growing +2.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Anbio Biotechnology Class A (NNNN) generate?
The free cash flow of Anbio Biotechnology Class A is −$6.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Anbio Biotechnology Class A (NNNN) hold?
Anbio Biotechnology Class A holds more cash than debt, $7.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Anbio Biotechnology Class A Ordinary Shares in the live analysis
One click puts Anbio Biotechnology Class A Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026